Teofilo Raad serves as President, Chief Executive Officer, Director of the Company. He has more than 20 years of commercial health care and life science leadership experience and most recently served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the United States and Japan. Earlier in his career he also gained direct launch experience with Sporanox, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the Pulmatrix programs. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management.
As the President, Chief Executive Officer et Director of Pulmatrix Inc, the total compensation of Teofilo Raad at Pulmatrix Inc is $823,367. There are no executives at Pulmatrix Inc getting paid more.
Teofilo Raad is 50, he's been the President, Chief Executive Officer et Director of Pulmatrix Inc since 2019. There are 13 older and 2 younger executives at Pulmatrix Inc. The oldest executive at Pulmatrix Inc is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, 72, who is the Founder & Member of Scientific Advisory Board.
Teofilo's mailing address filed with the SEC is C/O PULMATRIX, INC., 99 HAYDEN AVE, , LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Pulmatrix Inc have traded over $4,537,500 worth of Pulmatrix Inc stock and bought 290,998 units worth $2,002,066 . The most active insiders traders include Steven Gillis, Terrance Mcguire et Innovative Sciences, Inc. O.... On average, Pulmatrix Inc executives and independent directors trade stock every 92 days with the average trade being worth of $521,728. The most recent stock trade was executed by David L. Hava on 20 March 2017, trading 2,263 units of PULM stock currently worth $5,001.
pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
Pulmatrix Inc executives and other stock owners filed with the SEC include: